Table 2.
Pair-wise odds ratios between seven treatments for acute myocardial infarction obtained by direct and multiple treatment comparisons with fixed effect and random effects analyses*
|
Fixed effect
|
Random effects
|
|||
|---|---|---|---|---|
| Treatment comparison | Direct comparisons | Multiple comparison | Direct comparisons | Multiple comparison |
| Streptokinase v: | ||||
| Alteplase | 1.00 (0.94 to 1.06) | 0.99 (0.94 to 1.06) | 0.89 (0.54 to 1.14) | 0.96 (0.74 to 1.10) |
| Accelerated alteplase | 0.86 (0.78 to 0.94) | 0.86 (0.78 to 0.93) | 0.84 (0.68 to 0.99) | |
| Streptokinase+alteplase | 0.96 (0.87 to 1.05) | 0.96 (0.87 to 1.05) | 0.97 (0.75 to 1.25) | |
| Reteplase | 0.95 (0.79 to 1.12) | 0.90 (0.80 to 1.01) | 0.88 (0.65 to 1.06) | |
| Tenecteplase | 0.86 (0.74 to 1.00) | 0.85 (0.57 to 1.17) | ||
| PCTA | 0.52 (0.36 to 0.73) | 0.63 (0.52 to 0.77) | 0.49 (0.20 to 0.91) | 0.62 (0.47 to 0.77) |
| Alteplase v: | ||||
| Accelerated alteplase | 0.86 (0.77 to 0.95) | 0.88 (0.70 to 1.19) | ||
| Streptokinase+alteplase | 0.96 (0.86 to 1.07) | 1.02 (0.78 to 1.51) | ||
| Reteplase | 0.90 (0.79 to 1.02) | 0.92 (0.70 to 1.24) | ||
| Tenecteplase | 0.86 (0.73 to 1.01) | 0.90 (0.61 to 1.35) | ||
| PCTA | 0.63 (0.25 to 1.29) | 0.64 (0.51 to 0.77) | 0.65 (0.49 to 0.86) | |
| Accelerated alteplase v: | ||||
| Streptokinase+alteplase | 1.12 (1.00 to 1.25) | 1.12 (1.01 to 1.24) | 1.16 (0.91 to 1.55) | |
| Reteplase | 1.02 (0.90 to 1.16) | 1.05 (0.94 to 1.17) | 1.04 (0.81 to 1.28) | |
| Tenecteplase | 1.01 (0.88 to 1.14) | 1.01 (0.89 to 1.14) | 1.01 (0.74 to 1.35) | |
| PCTA | 0.81 (0.64 to 1.02) | 0.74 (0.61 to 0.89) | 0.79 (0.55 to 1.05) | 0.73 (0.59 to 0.90) |
| Streptokinase+alteplase v: | ||||
| Reteplase | 0.94 (0.82 to 1.07) | 0.92 (0.62 to 1.19) | ||
| Tenecteplase | 0.90 (0.76 to 1.05) | 0.89 (0.57 to 1.27) | ||
| PCTA | 0.66 (0.53 to 0.81) | 0.64 (0.45 to 0.85) | ||
| Reteplase v: | ||||
| Tenecteplase | 0.96 (0.82 to 1.13) | 0.98 (0.68 to 1.43) | ||
| PCTA | 0.71 (0.57 to 0.87) | 0.71 (0.53 to 0.94) | ||
| Tenecteplase v PCTA | 0.74 (0.58 to 0.92) | 0.74 (0.50 to 1.03) | ||
PCTA= primary percutaneous transluminal coronary angioplasty.
*
Empty cells represent pair-wise comparisons that have not been evaluated in trials (fixed effect) or for which there are fewer than three trials (random effects).